Immunotherapies are opening new ways to treat cancer, enabling us to target disease like never before and in cancers where progress has been elusive for years. Here, Novartis's chief executive explains why he decided to charge $475,000 for one such breakthrough.
from Forbes Real Time //www.forbes.com/sites/sciencebiz/2017/09/01/novartis-ceo-heres-how-i-handled-a-milestone-in-pediatric-cancer/
via IFTTT
No comments:
Post a Comment